momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	1/24/2006 9:57:31 PM
	Read Replies (1) of 12215

Rick, We just might have a promising cancer vaccine here... I haven't looked yet to see whether it qualifies as a cancer vax or if it is just a vaccination against some microbe which leads to the cancer... ++++++++++++++++++++++++++++ * 09:26 ET Accentia Biopharmaceuticals trading up premarket following phase 2 data on BiovaxID (ABPI) 6.91 :The co announces a subsidiary Biovest International (OTCBB: BVTI), reports follow-up data to a Phase 2 trial conducted by the National Cancer Institute that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients. The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50% chance of surviving 3 years and 20% chance of surviving 5 years. The data were published in a recent edition of Nature Medicine (Nat Med.2005; 11(9):986-91). Of the 26 patients in the study, 23 received vaccinations with BiovaxID commencing at least three months after completing their last chemotherapy and Rituxan treatments. Upon the 46-month (3.8-year) follow-up, the overall survival rate was 89%.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next